A MODULAR PHASE I/II OPEN-LABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO
EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF
AZD5492, A T CELL-ENGAGING ANTIBODY TARGETING CD20 IN SUBJECTS WITH RELAPSED
OR REFRACTORY B-CELL MALIGNANCIES (TITANIUM)
- Registry ID
- D9960C00001
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- ASTRAZENECA CANADA INC
- Start date
- 2024-12-06
- Last update
- 2024-06-28
Conditions
Related clinical trials
- A PHASE I TRIAL OF CLIC-2201 FOR THE TREATMENT OF RELAPSED/REFRACTORY B CELL
MALIGNANCIES
- FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF THE BTK DEGRADER, ABBV-101, IN PARTICIPANTS WITH B-CELL MALIGNANCIES
- A FIRST-IN-HUMAN MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF ABBV-319 IN B-CELL MALIGNANCIES
- A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND -EXPANSION STUDY OF THE BRUTON TYROSINE KINASE TARGETED PROTEIN DEGRADER BGB-16673 IN PATIENTS WITH B-CELL MALIGNANCIES
- A MULTICENTER, OPEN-LABEL, PHASE 2 BASKET STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK¿2140 AS A MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH AGGRESSIVE AND INDOLENT B-CELL MALIGNANCIES
- A PHASE 1/2 DOSE ESCALATION AND COHORT EXPANSION STUDY OF THE SAFETY AND EFFICACY OF ALLOGENEIC CRISPR-CAS9-ENGINEERED T CELLS (CTX110) IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES
View on source registry